雄激素剥夺治疗联合立体定向体部放疗对比单纯立体定向体部放疗治疗激素敏感性寡复发前列腺癌(RADIOSA):一项随机、开放标签、2期临床试验
RADIOSA是一项在意大利米兰欧洲肿瘤研究所开展的随机、开放标签、2期试验,纳入105例异时性寡复发激素敏感性前列腺癌患者,1:1随机接受单纯立体定向体部放疗(SBRT)或SBRT联合6个月雄激素剥夺治疗(ADT)。中位随访31个月,SBRT联合ADT组的中位临床无进展生存期为32.2个月,单纯SBRT组为15.1个月,风险比为0.43。
要点
- SBRT联合6个月ADT较单纯SBRT改善临床无进展生存期,风险比为0.43。
- 联合组与单纯SBRT组的中位临床无进展生存期分别为32.2个月和15.1个月。
- 联合组发生1例3级泌尿生殖系统不良事件(左侧输尿管狭窄)。
核心结论
- RADIOSA试验是首个在异时性寡转移激素敏感性前列腺癌中报告SBRT联合短程ADT改善临床无进展生存期的随机试验,但经过仔细选择的患者可能仍可从单纯SBRT中获益。
- RADIOSA试验通过证明临床无进展生存期改善,强化了转移导向治疗在延迟全身治疗升级中的作用,并强调需要进一步研究以确定ADT的最佳持续时间及识别预测单纯SBRT反应的生物标志物。
研究设计与样本
- RADIOSA研究是一项在意大利米兰欧洲肿瘤研究所(IRCCS)开展的单中心、随机、开放标签、对照2期试验。
- 关键入选标准包括组织学证实的初诊前列腺腺癌、根治性局部前列腺治疗后生化进展、盆腔淋巴结复发、区域外淋巴结复发、下一代影像学显示骨转移且病灶最多三个、ECOG体能状态0-1分、年龄18岁及以上。
- 参与者按前列腺特异性膜抗原倍增时间(≤3个月 vs >3个月)、转移灶定位(淋巴结 vs 骨)和诊断影像(正电子发射断层扫描 vs MRI)分层,使用计算机生成的随机数按1:1随机分配至单纯SBRT组或SBRT联合6个月ADT组。
- SBRT方案为30 Gy分3次隔日照射(考虑α/β比值为1.5 Gy,2 Gy分次等效剂量为98.6 Gy,生物有效剂量>100 Gy),或根据疾病部位给予等效方案;SBRT联合ADT组在SBRT开始前1周内接受促黄体生成素释放激素类似物治疗6个月。
- 主要终点为临床无进展生存期,所有分析遵循改良意向治疗原则,纳入分配至治疗组且有可用数据的全部患者;试验注册号为ClinicalTrials.gov NCT02680587,已完成。
主要发现
- 2019年8月1日至2023年4月30日,共评估218例患者资格,排除113例,入组105例并随机分配(52例至单纯SBRT组,53例至SBRT联合ADT组);3例失访,每组各51例纳入主要终点评估。
- 入组时中位年龄为70岁(IQR 65-75);未收集种族和民族数据。
- 两组中位随访均为31个月(IQR 16-36),单纯SBRT组中位临床无进展生存期为15.1个月(95% CI 12.4-22.8),SBRT联合ADT组为32.2个月(22.4-未达到)(风险比0.43 [95% CI 0.26-0.72],p=0.0010)。
- 报告1例1级胃肠道不良事件(单纯SBRT组)和1例3级泌尿生殖系统不良事件(左侧输尿管狭窄,SBRT联合ADT组),未观察到晚期毒性。
- 报告22例1级ADT相关不良事件,末次随访时均已缓解;未记录治疗相关死亡。
关键数值与推荐
- SBRT方案为30 Gy分3次隔日照射,2 Gy分次等效剂量为98.6 Gy(α/β比值1.5 Gy),生物有效剂量>100 Gy。
- SBRT联合ADT组在SBRT开始前1周内接受促黄体生成素释放激素类似物治疗6个月。
- 分层因素包括前列腺特异性膜抗原倍增时间(≤3个月 vs >3个月)、转移灶定位(淋巴结 vs 骨)和诊断影像(正电子发射断层扫描 vs MRI)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需要进一步研究以确定ADT的最佳持续时间并识别预测单纯SBRT反应的生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastasis-directed therapy by stereotactic body radiotherapy (SBRT) has been shown to improve clinical outcomes in the oligometastatic prostate cancer setting. We aimed to investigate whether short-course androgen deprivation therapy (ADT) and SBRT at all oligometastatic sites versus SBRT alone improves clinical progression-free survival in men with metachronous oligorecurrent hormone-sensitive prostate cancer. METHODS: The RADIOSA study was a single-centre, randomised, open-label, controlled phase 2 trial done in the European Institute of Oncology, IRCCS, Milan, Italy. Key eligibility criteria were histologically proven initial diagnosis of adenocarcinoma of the prostate, biochemical progression after radical local prostate treatment, nodal relapse in the pelvis, extra-regional nodal relapse, bone metastases at next-generation imaging with a maximum of three lesions, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and age 18 years or older. Participants were stratified according to prostate-specific membrane antigen doubling time (≤3 vs >3 months), metastases localisation (node vs bone), and diagnostic imaging (positron emission tomography vs MRI) and were randomly assigned (1:1) using a computer-generated random number to SBRT alone or SBRT in combination with 6 months of ADT. For SBRT treatment, a schedule of 30 Gy in three fractions every other day (with the equivalent dose in 2 Gy fractions being 98·6 Gy, considering α/β ratio of 1·5 Gy and biologically effective dose of >100 Gy), or equivalent regimens depending on disease site location, was administered. Patients in the SBRT with ADT group received 6 months of ADT with a luteinising hormone-releasing hormone analogue within 1 week before the start of SBRT. The allocated treatment was not masked. The primary outcome measure was clinical progression-free survival. All analyses followed a modified intention-to-treat principle, consisting of all patients assigned to a treatment group who had available data. The trial is registered at ClinicalTrials.gov, NCT02680587, and is complete. FINDINGS: Between Aug 1, 2019, and April 30, 2023, 218 patients were assessed for eligibility, 113 were excluded, and 105 were enrolled and randomly assigned to an intervention (52 to SBRT only and 53 to SBRT with ADT). Three patients were lost to follow-up and 51 patients in each group were assessed for the primary outcome. The median age at study enrolment was 70 years (IQR 65-75); data on race and ethnicity were not collected. With a median follow-up of 31 months (IQR 16-36) for both groups, the median clinical progression-free survival was 15·1 months (95% CI 12·4-22·8) for the SBRT group versus 32·2 months (22·4-not reached) for the SBRT with ADT group (hazard ratio 0·43 [95% CI 0·26-0·72], p=0·0010]). One gastrointestinal grade 1 adverse event (SBRT group) and one genitourinary grade 3 adverse event (left ureter stenosis, SBRT with ADT group) were reported, with no late toxicities observed. 22 grade 1 ADT-related adverse events were reported, all of which had resolved at the last follow-up. No treatment-related deaths were recorded. INTERPRETATION: To our knowledge, the RADIOSA trial represents the first randomised trial in the metachronous oligometastatic hormone-sensitive prostate cancer setting to report improved clinical progression-free survival with the combination of SBRT and a short course of ADT, although carefully selected patients might still benefit from SBRT alone. By demonstrating improved clinical progression-free survival, the RADIOSA trial reinforces the role of metastasis-directed therapy in delaying systemic treatment escalation. Additionally, it underscores the need for further studies to determine the optimal duration of ADT and identify biomarkers predicting response to SBRT alone. FUNDING: Italian Association of Cancer Research.
引用
- Marvaso G, Corrao G, Zaffaroni M, et al. ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol. 2025. PMID: 40049196. doi:10.1016/S1470-2045(24)00730-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。